|Day Low/High||17.00 / 18.85|
|52 Wk Low/High||7.35 / 27.50|
In 2017, McCamant's model portfolio rose 65%, while his trader's portfolio rose 98%.
Investors in Sangamo Therapeutics Inc saw new options begin trading this week, for the July 20th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the SGMO options chain for the new July 20th contracts and identified one put and one call contract of particular interest.
Bioverativ Inc., a Sanofi company dedicated to transforming the lives of people with rare blood disorders, and Sangamo Therapeutics, Inc.
There is no question that we are becoming extended and ripe for some profit taking.
Investors in Sangamo Therapeutics Inc saw new options become available this week, for the June 15th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the SGMO options chain for the new June 15th contracts and identified one put and one call contract of particular interest.
The game plan is to spot the charts that have more room to run.
Wall Street discounting talk of bombing Syria from president.
Whether this market continues to bounce is going to depend a great degree on the FAANG names.
Many stocks are already at support levels and are offering opportunities to start some positions.
Study provided proof of concept for development of SB-913 product candidate currently being evaluated in Phase 1/2 clinical trial
4 stocks on my shopping list for when conditions improve.
Analyst ratings can sometimes be complicated, and we here at ETF Channel have noticed a bit of a paradox with Sangamo Therapeutics Inc . The average 12-month price target for SGMO — averaging the work of 6 analysts — reveals an average price target of $23.50/share.
The market's reaction to James Bullard's comments this morning is following an all-too-common pattern.
Kite, a Gilead Company (Nasdaq:GILD) and Sangamo Therapeutics, Inc.
-- Kite to Receive Exclusive License to Leverage Sangamo's Gene Editing Technology in Allogeneic and Autologous Cell Therapy Programs in Oncology --
Here's what you need to know now for Wednesday, Feb. 14.
It's hard to believe the bounce will continue to run in V-shaped fashion.
It is a very different market environment now which can be very rewarding depending on your style.
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.